title: [Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years].
abstract: Case 1 is a 78-year-old woman in whom lung adenocarcinoma with multiple brain metastasis (cT2N3M1, stage IV) was diagnosed. She was treated with Gefitinib alone. Her lung tumor and metastatic brain lesions decreased 6 months after the start of therapy. She has no recurrence and is still alive with a good performance status after 25 months. Case 2 is an 80-year-old woman in whom lung adenocarcinoma with multiple brain (cT2N3M1, stage IV) was diagnosed. She was also treated with Gefitinib alone and her lung tumor and metastatic brain becomes improved 6 months after the start of therapy. She maintained a good performance status for more than 2 years (29 months). However, 29 months after beginning treatment, she had recurrence in bone and died 2 months later, 31 months after the start of therapy. The prognosis of non-small cell lung cancer with multiple brain metastasis is very poor and the efficacy of chemotherapy for the treatment of multiple brain metastases is limited, and longterm survival remains disappointing. We report two lung adenocarcinoma patients with multiple brain metastasis who survived more than 2 years by treatment with Gefitinib alone.
authors.affiliation: Division of Respiratory Medicine, Respiratory and Stress Care Center, Kagoshima University Hospital.
authors.forename: Wataru
authors.initials: W
authors.lastname: Matsuyama
authors.forename: Masuki
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Kentarou
authors.initials: K
authors.lastname: Machida
authors.forename: Hideo
authors.initials: H
authors.lastname: Mitsuyama
authors.forename: Masaki
authors.initials: M
authors.lastname: Watanabe
authors.forename: Ikkou
authors.initials: I
authors.lastname: Higashimoto
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Osame
authors.forename: Kimiyoshi
authors.initials: K
authors.lastname: Arimura
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary*; D004334:Drug Administration Schedule; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011799:Quinazolines / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D017741:Survivors
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib